NASDAQ:ALIM Alimera Sciences (ALIM) Stock Forecast, Price & News $3.21 +0.20 (+6.64%) (As of 09/26/2023 ET) Add Compare Share Share Today's Range$2.94▼$3.2450-Day Range$3.01▼$3.8052-Week Range$1.30▼$6.25Volume70,139 shsAverage Volume236,584 shsMarket Capitalization$28.25 millionP/E RatioN/ADividend YieldN/APrice Target$5.83 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Alimera Sciences MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside81.7% Upside$5.83 Price TargetShort InterestHealthy3.13% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 2 Articles This WeekInsider TradingAcquiring Shares$1.96 M Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.01) to $0.39 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.23 out of 5 starsMedical Sector356th out of 964 stocksPharmaceutical Preparations Industry151st out of 445 stocks 3.5 Analyst's Opinion Consensus RatingAlimera Sciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.83, Alimera Sciences has a forecasted upside of 81.7% from its current price of $3.21.Amount of Analyst CoverageAlimera Sciences has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted3.13% of the float of Alimera Sciences has been sold short.Short Interest Ratio / Days to CoverAlimera Sciences has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Alimera Sciences has recently decreased by 82.55%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAlimera Sciences does not currently pay a dividend.Dividend GrowthAlimera Sciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ALIM. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 2 news articles for Alimera Sciences this week, compared to 2 articles on an average week. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Alimera Sciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,962,810.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders31.40% of the stock of Alimera Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Alimera Sciences are expected to grow in the coming year, from ($0.01) to $0.39 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Alimera Sciences is -0.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Alimera Sciences is -0.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Alimera Sciences (NASDAQ:ALIM) StockAlimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals. It operates through United States, internationally, and Operating Cost segments. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician offices, pharmacies, clinics, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. Alimera Sciences, Inc. was incorporated in 2003 and is headquartered in Alpharetta, Georgia.Read More ALIM Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ALIM Stock News HeadlinesSeptember 23, 2023 | americanbankingnews.comAlimera Sciences (NASDAQ:ALIM) Stock Crosses Above 200-Day Moving Average of $2.65September 17, 2023 | americanbankingnews.comAlimera Sciences, Inc. (NASDAQ:ALIM) Major Shareholder Purchases $1,962,810.00 in StockSeptember 26, 2023 | Micro-Cap Stock Trader (Ad)Unlock the treasure on Mount Olympus with this little-known mining stock.Investor Find Lithium Gold and Crush the Bear Market with 32k Metric TonsSeptember 14, 2023 | finance.yahoo.comAlimera Sciences, Inc.'s (NASDAQ:ALIM) Profit OutlookSeptember 5, 2023 | finance.yahoo.comAlimera Sciences to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceAugust 23, 2023 | finance.yahoo.comAltium Capital Management LP Acquires New Stake in Alimera Sciences IncAugust 18, 2023 | finance.yahoo.comShareholders in Alimera Sciences (NASDAQ:ALIM) are in the red if they invested five years agoAugust 14, 2023 | markets.businessinsider.comThe Latest Analyst Ratings for Alimera SciencesSeptember 26, 2023 | Micro-Cap Stock Trader (Ad)Unlock the treasure on Mount Olympus with this little-known mining stock.Investor Find Lithium Gold and Crush the Bear Market with 32k Metric TonsAugust 13, 2023 | finance.yahoo.comAlimera Sciences, Inc. (NASDAQ:ALIM) Q2 2023 Earnings Call TranscriptAugust 11, 2023 | finance.yahoo.comStonepine Capital Management, LLC Acquires New Stake in Alimera Sciences IncAugust 11, 2023 | finance.yahoo.comQ2 2023 Alimera Sciences Inc Earnings CallAugust 10, 2023 | finanznachrichten.deAlimera Sciences, Inc.: Alimera Sciences Reports Second Quarter 2023 ResultsAugust 10, 2023 | markets.businessinsider.comHere's what Wall Street expects from Alimera Sciences's earnings reportAugust 10, 2023 | msn.comAlimera Sciences GAAP EPS of -$1.32 misses by $1.33, revenue of $17.5M misses by $2.95MAugust 10, 2023 | finance.yahoo.comAlimera Sciences Reports Second Quarter 2023 ResultsAugust 10, 2023 | finance.yahoo.comAlimera Sciences (ALIM) Reports Q2 Loss, Lags Revenue EstimatesAugust 9, 2023 | benzinga.comPreview: Alimera Sciences's EarningsAugust 4, 2023 | gurufocus.comVelan Capital Investment Management LP Boosts Stake in Alimera Sciences IncAugust 4, 2023 | gurufocus.comCaligan Partners LP Reduces Stake in Alimera Sciences IncAugust 2, 2023 | finance.yahoo.comAlimera Sciences to Report Second Quarter 2023 Financial Results on August 10, 2023, and Provide Corporate UpdateJune 12, 2023 | msn.comAlliance Global Partners Upgrades Alimera Sciences (ALIM)June 12, 2023 | msn.comBenzinga's Top Ratings Upgrades, Downgrades For June 12, 2023June 12, 2023 | markets.businessinsider.comAlliance Global Partners Upgrades Alimera Sciences: Here's What You Need To KnowJune 12, 2023 | markets.businessinsider.comExpert Ratings for Alimera SciencesJune 8, 2023 | finance.yahoo.comAlimera Sciences (ALIM) Is Attractively Priced Despite Fast-paced MomentumMay 25, 2023 | finance.yahoo.comAlimera (ALIM) Completes Enrollment in Eye Disease StudySee More Headlines Receive ALIM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alimera Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address ALIM Company Calendar Last Earnings8/10/2023Today9/26/2023Next Earnings (Estimated)11/13/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ALIM CUSIPN/A CIK1267602 Webwww.alimerasciences.com Phone(678) 990-5740Fax678-990-5744Employees150Year Founded2003Price Target and Rating Average Stock Price Forecast$5.83 High Stock Price Forecast$8.00 Low Stock Price Forecast$4.50 Forecasted Upside/Downside+81.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($3.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-18,110,000.00 Net Margins-40.94% Pretax Margin-40.88% Return on EquityN/A Return on Assets-23.44% Debt Debt-to-Equity RatioN/A Current Ratio3.23 Quick Ratio3.16 Sales & Book Value Annual Sales$54.13 million Price / Sales0.52 Cash FlowN/A Price / Cash FlowN/A Book Value($5.72) per share Price / Book-0.56Miscellaneous Outstanding Shares8,800,000Free Float6,038,000Market Cap$28.25 million OptionableOptionable Beta1.40 Social Links 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Richard S. Eiswirth Jr. (Age 55)Pres, CEO & Director Comp: $597.87kMr. David R. Holland (Age 59)Co-Founder, Chief Marketing Officer and Sr. VP of Corp. Communications & Managed Markets Comp: $413.5kDr. Philip Ashman Ph.D. (Age 58)COO & Sr. VP of Commercial Operations - Europe Comp: $389.86kMr. Russell L. Skibsted M.B.A. (Age 64)Sr. VP & CFO Christopher S. VisickVP, Gen. Counsel & Sec.Dr. David Dyer M.D.Chief Retina SpecialistMore ExecutivesKey CompetitorsKALA BIONASDAQ:KALASio Gene TherapiesNASDAQ:SIOXEquilliumNASDAQ:EQGenprexNASDAQ:GNPXLiminal BioSciencesNASDAQ:LMNLView All CompetitorsInsiders & InstitutionsCaligan Partners LpBought 579,000 shares on 9/14/2023Total: $1.96 M ($3.39/share)Osaic Holdings Inc.Bought 11,565 shares on 8/21/2023Ownership: 0.131%Perritt Capital Management Inc.Sold 8,000 shares on 8/14/2023Ownership: 0.114%Velan Capital Investment Management LPBought 1,401,901 shares on 8/11/2023Ownership: 18.838%Renaissance Technologies LLCBought 28,322 shares on 8/11/2023Ownership: 1.472%View All Insider TransactionsView All Institutional Transactions ALIM Stock - Frequently Asked Questions Should I buy or sell Alimera Sciences stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Alimera Sciences in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ALIM shares. View ALIM analyst ratings or view top-rated stocks. What is Alimera Sciences' stock price forecast for 2023? 2 equities research analysts have issued 12-month target prices for Alimera Sciences' shares. Their ALIM share price forecasts range from $4.50 to $8.00. On average, they anticipate the company's share price to reach $5.83 in the next twelve months. This suggests a possible upside of 81.7% from the stock's current price. View analysts price targets for ALIM or view top-rated stocks among Wall Street analysts. How have ALIM shares performed in 2023? Alimera Sciences' stock was trading at $2.71 at the beginning of 2023. Since then, ALIM stock has increased by 18.5% and is now trading at $3.21. View the best growth stocks for 2023 here. Are investors shorting Alimera Sciences? Alimera Sciences saw a drop in short interest in the month of August. As of August 31st, there was short interest totaling 121,700 shares, a drop of 82.5% from the August 15th total of 697,400 shares. Based on an average daily trading volume, of 43,000 shares, the short-interest ratio is presently 2.8 days. Currently, 3.1% of the shares of the stock are sold short. View Alimera Sciences' Short Interest. When is Alimera Sciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023. View our ALIM earnings forecast. How were Alimera Sciences' earnings last quarter? Alimera Sciences, Inc. (NASDAQ:ALIM) issued its quarterly earnings results on Thursday, August, 10th. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of $0.06 by $0.50. The biopharmaceutical company had revenue of $17.54 million for the quarter, compared to analysts' expectations of $20.36 million. When did Alimera Sciences' stock split? Alimera Sciences's stock reverse split before market open on Friday, November 15th 2019. The 1-15 reverse split was announced on Thursday, November 7th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, November 14th 2019. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What is Rick Eiswirth's approval rating as Alimera Sciences' CEO? 2 employees have rated Alimera Sciences Chief Executive Officer Rick Eiswirth on Glassdoor.com. Rick Eiswirth has an approval rating of 100% among the company's employees. This puts Rick Eiswirth in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Alimera Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Alimera Sciences investors own include EyePoint Pharmaceuticals (EYPT), OPKO Health (OPK), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Advanced Micro Devices (AMD), Amarin (AMRN), AngloGold Ashanti (AU), SSR Mining (SSRM), ADMA Biologics (ADMA) and Cellectar Biosciences (CLRB). What is Alimera Sciences' stock symbol? Alimera Sciences trades on the NASDAQ under the ticker symbol "ALIM." Who are Alimera Sciences' major shareholders? Alimera Sciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include Velan Capital Investment Management LP (18.84%), Renaissance Technologies LLC (1.47%), Geode Capital Management LLC (0.67%), Osaic Holdings Inc. (0.13%), Osaic Holdings Inc. (0.13%) and Perritt Capital Management Inc. (0.11%). Insiders that own company stock include Adam Morgan, Alto Investors Lp Palo, Caligan Partners Lp, James R Largent, John Philip Jones, Philip Ashman, Richard S Eiswirth Jr and Stanley Morgan. View institutional ownership trends. How do I buy shares of Alimera Sciences? Shares of ALIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Alimera Sciences' stock price today? One share of ALIM stock can currently be purchased for approximately $3.21. How much money does Alimera Sciences make? Alimera Sciences (NASDAQ:ALIM) has a market capitalization of $28.25 million and generates $54.13 million in revenue each year. The biopharmaceutical company earns $-18,110,000.00 in net income (profit) each year or ($3.32) on an earnings per share basis. How many employees does Alimera Sciences have? The company employs 150 workers across the globe. How can I contact Alimera Sciences? Alimera Sciences' mailing address is 6120 WINDWARD PARKWAY STE 290, ALPHARETTA GA, 30005. The official website for the company is www.alimerasciences.com. The biopharmaceutical company can be reached via phone at (678) 990-5740, via email at scottg@coreir.com, or via fax at 678-990-5744. This page (NASDAQ:ALIM) was last updated on 9/26/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alimera Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.